Three Motley Fool contributors believe they've identified healthcare stocks in the latter category. Here's why they think Eli ...

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in ... to our mission of empowering investor success. We provide a platform for our authors to report ...

This analysis is based on information available up to January 17, 2025, and market conditions may have changed since then. Gain an edge in your investment decisions with InvestingPro’s in-depth ...

Hanmi Pharmaceutical develops obesity drugs to increase muscle while reducing fat Hanmi Pharmaceutical pioneers innovative ...

The Zepbound® formulation had a strength of ... editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments ...

We recently published a list of Jim Cramer Discussed These 18 Stocks As Inflation Dropped. In this article, we are going to ...

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...